LUMO,Lumos Pharma, Inc. | Healthcare

Healthcare

LUMO

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Lumos Pharma, Inc.LUMO

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases.

Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.

The company is headquartered in Austin, Texas.

Latest News >

Murphy USA Q4 Earnings, Revenue Fall; Shares Down After Hours

Feb 5, 2025

04:52 PM EST, 02/05/2025 (MT Newswires) -- Murphy USA ( MUSA ) reported Q4 earnings late Wednesday of $6.96 per diluted share, down from $7 a year earlier. Two analysts polled by FactSet expected $6.67. Operating revenue for the quarter ended Dec. 31 fell to $4.71 billion from $5.07 billion a year earlier. Analysts surveyed by FactSet expected $4.90 billion....

Resmed Insider Sold Shares Worth $484,220, According to a Recent SEC Filing

Feb 5, 2025

04:51 PM EST, 02/05/2025 (MT Newswires) -- Peter C Farrell, Director, on February 05, 2025, sold 2,000 shares in Resmed ( RMD ) for $484,220. Following the Form 4 filing with the SEC, Farrell has control over a total of 77,218 common shares of the company, with 77,218 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/943819/000112760225003232/xslF345X05/form4.xml ...

Mid-America Apartment Communities Q4 Core AFFO Declines, Revenue Rises; 2025 Core AFFO Guidance Issued

Feb 5, 2025

04:52 PM EST, 02/05/2025 (MT Newswires) -- Mid-America Apartment Communities ( MAA ) reported late Wednesday Q4 core adjusted funds from operations of $2.03 per diluted share, down from $2.10 a year earlier. Analysts polled by FactSet expected adjusted FFO of $2.03. Rental and other property revenue for the quarter ended Dec. 31 was $549.8 million, up from $542.2 million...

TotalEnergies CEO doubles down on US LNG, downplays Trump tariff fears

Feb 5, 2025

* Plans to expand Cameron, Rio Grande projects over next decade * CEO says Trump will be pragmatic * Company LNG portfolio can handle trade disruptions * Urges Europe not to ban Russian LNG before 2027 By America Hernandez LONDON, Feb 5 (Reuters) - TotalEnergies will expand its investment in U.S. liquefied natural gas over the next decade as the...